Download PDF
Thromb Haemost 1975; 34(03): 634-643
DOI: 10.1055/s-0038-1651453
Original Article
Schattauer GmbH

Indications for Antifibrinolytic Therapy[*]

C. R. M Prentice
1   University Department of Medicine, Royal Infirmary, Glasgow, G4 0SF, Scotland
› Author Affiliations
Further Information

Publication History

Received 01 July 1975

Accepted 01 July 1975

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

 

* Presented at the Postgraduate Course and Workshop “Progress in Fibrinolysis”, Milan, March 6–8, 1975.


 

  • References

  • 1 Abe T, Sato A, Hazama M, and Matsumma T. 1962; Effects of epsilon aminocaproic acid in haemophilia. Lancet 2: 405.
    PubMedGoogle Scholar
  • 2 Abbondi F. B, Hagan J. J, Philips M, and de Renzo E. C. 1959; Inhibition of plasmin, trypsin and the streptokinase-activated fibrinolytic system by epsilon-aminocaproic acid. Archives of Biochemistry and Biophysics 82: 153.
    CrossrefPubMedGoogle Scholar
  • 3 Albrechtsen O. K, and Thaysen J. H. 1955; Fibrinolytic activity in human saliva. Acta Physiologica Scandinavica 35: 138.
    CrossrefPubMedGoogle Scholar
  • 4 Alkjaersig N, Fletcher A. P, and Sherry S. 1959; Epsilon-aminocaproic acid, an inhibitor of plasminogen activation. Journal of Biological Chemistry 234: 832.
    PubMedGoogle Scholar
  • 5 Amris C. J, and Hilden M. 1967; Inhibition of thromboplastic activity by trasylol. Scandinavian Journal of Haematology 4: 3.
    PubMedGoogle Scholar
  • 6 Andersson L. 1962 Studies in fibrinolysis in urinary tract disease and its treatment with epsilon aminocaproic acid. Acta Chirurgica Scandinavica. Suppl., 301.
    PubMedGoogle Scholar
  • 7 Andersson L, and Nilsson I. M. 1961; Effect of E-amino-n-caproic acid (EACA) on fibrinolysis and bleeding conditions in prostatic disease. Acta Chirurgica Scandinavica 121: 291.
    PubMedGoogle Scholar
  • 8 Andersson L, Nilsson I. M, Colleen S, Cranstrand B, and Melander B. 1968; Hole of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Annals of New York Academy of Sciences 146: 642.
    CrossrefPubMedGoogle Scholar
  • 9 Barkhan P. 1964; Haematuria in a haemophiliac treated with E-aminocaproic acid. Lancet 2: 1061.
    PubMedGoogle Scholar
  • 10 Basu H. K. 1971; Postpartum coagulation failure. British Medical Journal 3: 251.
    PubMedGoogle Scholar
  • 11 Biggs R, Macfarlane R. G, and Pilling J. 1947; Lancet 1: 402.
    PubMed
  • 12 Blombäck B, Blombäck M, and Olson P. 1967; Action of a proteolytic enzyme inhibitor on blood coagulation in vitro . Thrombosis et Diathesis Haemorrhagica 18: 190.
    PubMedGoogle Scholar
  • 13 Callender S. T, Warner G. T, and Cope E. 1970; Treatment of monorrhagia with tranexamic acid. A double-blind trial. British Medical Journal 4: 214.
    CrossrefPubMedGoogle Scholar
  • 14 Collen D, Tytgat D, Claeys H, and Piessens R. 1972; Metabolism of plasminogen in healthy subjects: effect of tranexamic acid. Journal of Clinical Investigation 51: 1310.
    CrossrefPubMedGoogle Scholar
  • 15 Cooksey M. W, Perry C. B, and Raper A. B. 1966; Epsilon-aminocaproic acid therapy for dental extractions in haemophiliacs. British Medical Journal 2: 1633.
    CrossrefPubMedGoogle Scholar
  • 16 Cox H. T, Poller L, and Thomson J. M. 1967; Gastric fibrinolysis. A possible link with peptic ulcer. Lancet 1: 1300.
    PubMedGoogle Scholar
  • 17 Davidson J. F, McNicol G. P, Frank G. L, Anderson T. J, and Douglas A. S. 1969; Plasminogen-activator-producing tumour. British Medical Journal 1: 88.
    CrossrefPubMedGoogle Scholar
  • 18 Dubber A. H. C, McNicol G. P, Uttley D, and Douglas A. S. 1968; In vitro and in vivo studies with Trasylol, an anticoagulant and a fibrinolytic inhibitor. British Journal of Haematology 14: 31.
    CrossrefPubMedGoogle Scholar
  • 19 Egeblad K. 1966; Effects of Epsilon-aminocaproic acid on fibrin clot lysis. Thrombosis et Diathesis Haemorrhagica 15: 173.
    PubMedGoogle Scholar
  • 20 Fletcher A. P, Alkjaersig N, and Sherry S. 1962; Fibrinolytic mechanisms and the development of thrombolytic therapy. American Journal of Medicine 33: 738.
    CrossrefPubMedGoogle Scholar
  • 21 Forbes C. D, Barr R. D, Reid G, Thomson C, Prentice C. R. M, McNicol G. P, and Douglas A. S. 1972; Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. British Medical Journal 1: 311.
    PubMedGoogle Scholar
  • 22 Giordano N. D, Watkins R. S, Radivoyevitch M, and Goodsitt E. 1967; Dental extractions in haemophilic patients on aminocaproic acid prophylaxis. Oral Surgery, Oral Medicine and Oral Pathology 24: 171.
    CrossrefPubMedGoogle Scholar
  • 23 Gobbi F. 1967; Use and misuse of aminocaproic acid. Lancet 2: 472.
    PubMedGoogle Scholar
  • 24 Gordon A. M, McNicol G. P, Dubber A. H. C, McDonald G. A, and Douglas A. S. 1965; Clinical trials of epsilon aminocaproic acid in haemophilia. British Medical Journal 1: 1632.
    CrossrefPubMedGoogle Scholar
  • 25 Grossi C. E, Moreno A. H, and Rousselot L. M. 1961; Studies on spontaneous fibrinolytic activity in patients with cirrhosis of the liver and its inhibition by epsilon aminocaproic acid. Annals of Surgery 153: 383.
    CrossrefPubMedGoogle Scholar
  • 26 Grossi C. E, Rousselot L. M, and Panke W. 1964; Control of fibrinolysis during portocaval shunts. Journal of the American Medical Association 187: 1005.
    PubMedGoogle Scholar
  • 27 Hilgartner M. W. 1966; Intrarenal obstruction in haemophilia. Lancet 1: 486.
    PubMedGoogle Scholar
  • 28 Johnson A. L, Skoza L, and Claus E. 1962; Observations on epsilon aminocaproic acid. Thrombosis et Diathesis Haemorrhagica 7: 203.
    PubMedGoogle Scholar
  • 29 Konttinen Y. P. 1968. Fibrinolysis: Chemistry, Physiology, Pathology and Clinics Star. Tampere, Finland:
    Google Scholar
  • 30 Kullander S, and Nilsson I. M. 1970; Human placental transfer of an anti-fibrinolytic agent (AMCA). Acta obstetrica Gynecologica Scandinavica 49: 241.
    CrossrefPubMedGoogle Scholar
  • 31 Kwaan H. C, Cocco A, and Mendeloff A. I. 1964; Histologic demonstration of plasminogen activation in rectal bopsies from patients with active ulcerative colitis. Journal of Laboratory and Clinical Medicine 64: 877.
    PubMedGoogle Scholar
  • 32 Locksley H. B. 1966; Report on the co-operative study of intracranial aneurysms and subarachnoid hemorrhage. Section Y., Part II. Journal of Neurosurgery 25: 321.
    CrossrefPubMedGoogle Scholar
  • 33 Lucas O. N, Carroll R. T, Finkelmann A, and Tocantins L. M. 1962; Thrombosis et Diathesis. Haemorrhagica 8: 209.
    PubMedGoogle Scholar
  • 34 McKay D. G, and Müller-Berghaus G. 1967; Therapeutic implications of disseminated intravascular coagulation. American Journal of Cardiology 20: 392.
    CrossrefPubMedGoogle Scholar
  • 35 McNicol G. P. 1962; Disordered fibrinolytic activity and its control. Scottish Medical Journal 7: 266.
    CrossrefPubMedGoogle Scholar
  • 36 McNicol G. P, Alkjaersig N, Fletcher A. P, and Sherry S. 1961; Use of epsilon aminocaproic acid in management of postoperative haematuria. Journal of Urology 86: 829.
    CrossrefPubMedGoogle Scholar
  • 37 McNicol G. P, and Douglas A. S. 1972. Thrombolytic therapy and fibrinolytic inhibitors. In: Biggs R. (ed.) Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell; Oxford:
    Google Scholar
  • 38 McNicol G. P, Fletcher A. P, Alkjaersig N, and Sherry S. 1962; The absorption, distribution and excretion of epsilon aminocaproic acid (EACA) following its oral or intravenous administration to man. Journal of Laboratory and Clinical Medicine 58: 15.
    PubMedGoogle Scholar
  • 39 Markwardt F, Klocking H. P, and Landmann H. 1967; Vergleichende Untersuchungen über Antifibrinolytika. Thrombosis et Diathesis Haemorrhagica 15: 561.
    PubMedGoogle Scholar
  • 40 Moltke P. 1958; Plasminogen activators in animal meninges. Proceedings of the Society of Experimental Biology and Medicine 98: 377.
    PubMedGoogle Scholar
  • 41 Naeye R. L. 1962; Thrombotic state after a haemorrhagic diathesis, a possible complication of therapy with epsilon-aminocaproic acid. Blood 19: 694.
    PubMedGoogle Scholar
  • 42 Nilsson I. M, Andersson L, and Björkman S. E. 1966 Epsilon-aminocaproic acid (EACA) as a therapeutic agent. Based on 5 years clinical experience. Acta Medica Scandinavica. suppl. 448.
    PubMedGoogle Scholar
  • 43 Nilsson I. M, Björkman S. E, and Andersson L. 1961; Clinical experiences with ε-aminocaproic acid (EACA) as an antifibrinolytic agent. Acta Medica Scandinavica 170: 487.
    PubMedGoogle Scholar
  • 44 Nilsson L, and Rybo G. 1967; Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA). Acta Obstetrica Gynecologica Scandinavica 46: 572.
    CrossrefPubMedGoogle Scholar
  • 45 Okamoto S, and Okamoto U. 1962; Aminomethylcyclohexane carboxylic acid, a new potent inhibitor of fibrinolysis. Keio Journal of Medicine 11: 105.
    CrossrefPubMedGoogle Scholar
  • 46 Porter J. M, Acinapura A. J, Kapp J. P, and Silver D. 1966; Fibrinolytic activity of the spinal fluid and meninges. Surgical Forum 17: 425.
    PubMedGoogle Scholar
  • 47 Poulain M, and Josso F. 1966 Current studies in haemophilia. Proceedings of 3rd Congress World Federation of Haemophilia, Paris. Bibl. haemat. vol. 26, p. 115. Basel and New York.
    PubMedGoogle Scholar
  • 48 Prentice C. R. M, Lindsay R. M, Barr R. D, Forbes C. D, Kennedy A. C, McNicol G. P, and Douglas A. S. 1971; Renal complications in haemophilia and Christmas disease. Quarterly Journal of Medicine 40: 47.
    PubMedGoogle Scholar
  • 49 Prentice C. R. M, McNicol G. P, and Douglas A. S. 1970; Studies on the anticoagulant action of Aprotinin (Trasylol). Thrombosis et Diathesis Haemorrhagica 14: 265.
    PubMedGoogle Scholar
  • 50 Ratnoff O. D. 1961; Studies on the activation of Hageman factor. Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. Journal of Clinical Investigation 40: 803.
    CrossrefPubMedGoogle Scholar
  • 51 Ratnoff O. D. 1969; Epsilon aminocaproic acid – a dangerous weapon. New England Journal of Medicine 280: 1124.
    CrossrefPubMedGoogle Scholar
  • 52 Reid W. O, Hodge S. M, and Cerutti E. R. 1967; The use of EACA in preventing or reducing haemorrhages in the haemophiliac. Thrombosis et Diathesis Haemorrhagica 18: 179.
    PubMedGoogle Scholar
  • 53 Reid W. O, Lucas O. N, Francisco J, and Geisler P. H. 1964; The use of epsilon aminocaproic acid in the management of dental extractions in the haemophiliac. American Journal of the Medical Sciences 248: 184.
    CrossrefPubMedGoogle Scholar
  • 54 Rybo G. 1966; Plasminogen activators in the endometrium. Clinical aspects. Acta Obstetrica Gynecologica Scandinavica 45: 429.
    CrossrefPubMedGoogle Scholar
  • 55 Sack E, Spaet T. H, Gentile R. L, and Hudson P. B. 1962; Reduction of prostatectomy bleeding by epsilon aminocaproic acid. New England Journal of Medicine 266: 541.
    CrossrefPubMedGoogle Scholar
  • 56 Sato S, Ishibashi Y, Endo T, Watanabe T, and Nakajima K. 1959; Clinical use of epsilon-amino-n-caproic acid in metropathia haemorrhagica. Keio Journal of Medicine 8: 267.
    CrossrefPubMedGoogle Scholar
  • 57 Stark S. N, White J. G, Langer L, and Krivit W. 1965; Epsilon aminocaproic acid therapy as a cause of intrarenal obstruction in haematuria of haemophilia. Scandinavian Journal of Haematology 2: 99.
    PubMedGoogle Scholar
  • 58 Steichele D. F, and Herschlein H. J. 1961; Zur antifibrinolytischen Wirkung des Trypsin-Kallikrein-Inaktivators. Medizinische Welt 42: 2170.
    PubMedGoogle Scholar
  • 59 Steiger B, White J. G, and Krivit W. 1962; Epsilon-aminocaproic acid for hematuria in hemophilia. Lancet 82: 421.
    PubMedGoogle Scholar
  • 60 Sultan Y, Larrieu M. J, Meyer D, Caen J, and Bernard J. 1966 Current studies in haemophilia. Proceedings of 3rd Congress World Federation of Haemophilia, Paris, Bibl. haemat., vol. 26, p. 100. Basel and New York.
    PubMedGoogle Scholar
  • 61 Tavenner B. W. H. 1968; Epsilon aminocaproic acid in the treatment of haemophilia and Christmas disease with special reference to the extraction of teeth. British Dental Journal 124: 19.
    PubMedGoogle Scholar
  • 62 Tovi D. 1972 Studies on fibrinolysis in the central nervous system with special reference to intracranial haemorrhages and to the effect of antifibrinolytic drugs. Umea University Medical Dissertations. No. 8.
    PubMedGoogle Scholar
  • 63 Tsevrenis H, and Mandelaki H. 1965; Haematuria in a haemophiliac treated with ε-aminocaproic acid. Lancet 1: 610.
    PubMedGoogle Scholar
  • 64 van Itterbreek H, Vermylen J, and Verstraete M. 1968; High obstruction of urine flow as a complication of the treatment with fibrinolysis inhibitors of haematuria in haemophiliacs. Acta haematologca 39: 237.
    PubMedGoogle Scholar
  • 65 Vinnicombe J, and Shuttleworth K.E.D. 1966; a Aminocaproic acid in the control of haemorrhage after prostatectomy. Safety of aminocaproic acid – a controlled trial. Lancet 1: 232.
    PubMedGoogle Scholar
  • 66 Vinnicombe J, and Shuttleworth K. E. D. 1966; b Aminocaproic acid in the control of haemorrhage after prostactectomy. A controlled trial. Lancet 1: 230.
    PubMedGoogle Scholar
  • 67 Walsh P. N, Rizza C. R, Matthews J. M, Eipe J, Kernoff P. B. A, Coles M. D, Bloom A. L, Kaufman B. M, Beck P, Hanan C. M, and Biggs B. 1971; Epsilon-aminocaproic acid bherapy for dental extractions in haemophilia and Christmas disease. A double blind controlled trial. British Journal of Haematology 20: 463.
    CrossrefPubMedGoogle Scholar
  • 68 Wright F. W, Matthews J. M, and Brock L. G. 1971; Complications of hemophilic disorders affecting the renal tract. Radiology 98: 571.
    CrossrefPubMedGoogle Scholar